心脏骤停后基于装置预防发热的持续时间
该随机对照试验将院外心脏骤停(推定心源性)复苏后昏迷患者随机分为装置控温36小时组(先目标36°C 24小时,再目标37°C 12小时)与72小时组(先目标36°C 24小时,再目标37°C 48小时),或直至患者恢复意识。主要终点为随机化后90天内全因死亡或出院时脑功能分级(CPC)3或4级的复合终点:36小时组127/393例(32.3%),72小时组133/396例(33.6%),HR 0.99(95%CI 0.77–1.26),P=0.70。死亡率分别为29.5%与30.3%,3个月蒙特利尔认知评估中位数分别为26分与27分,不良事件发生率组间无显著差异。作者结论为36小时与72小时装置预防发热在死亡或严重残疾/昏迷比例上无显著差异。
要点
- 36小时组主要终点事件127/393例(32.3%),72小时组133/396例(33.6%),HR 0.99(95%CI 0.77–1.26),P=0.70。
- 36小时组死亡率29.5%,72小时组30.3%,组间无显著差异。
- 3个月蒙特利尔认知评估中位数:36小时组26分(四分位距24–29),72小时组27分(四分位距24–28)。
- 不良事件发生率组间无显著差异。
- 作者结论:心脏骤停后装置预防发热36小时或72小时,死亡或严重残疾/昏迷比例无显著差异。
适用人群与场景
- 院外心脏骤停(推定心源性)复苏后的昏迷患者。
诊断标准与关键阈值
- 脑功能分级(CPC)范围1–5分,分数越高残疾越严重;3或4级表示严重脑残疾或昏迷。
处置流程与药物剂量
- 36小时组:装置控温目标36°C持续24小时,随后目标37°C持续12小时,总干预时间36小时,或直至患者恢复意识。
- 72小时组:装置控温目标36°C持续24小时,随后目标37°C持续48小时,总干预时间72小时,或直至患者恢复意识。
研究设计与关键结果
- 随机对照试验:393例随机至36小时控温组,396例随机至72小时控温组。
- 主要终点(随机化后90天内全因死亡或出院时CPC 3或4级复合终点):36小时组127/393例(32.3%)vs 72小时组133/396例(33.6%),HR 0.99(95%CI 0.77–1.26),P=0.70。
- 次要终点死亡:36小时组29.5% vs 72小时组30.3%。
- 3个月蒙特利尔认知评估中位数:36小时组26分(四分位距24–29)vs 72小时组27分(四分位距24–28)。
- 不良事件发生率组间无显著差异。
证据类型、等级与局限
- 研究类型:随机对照试验(BOX,ClinicalTrials.gov NCT03141099),由Novo Nordisk Foundation资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:心脏骤停后装置预防发热36小时或72小时,死亡或严重残疾/昏迷比例无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Guidelines recommend active fever prevention for 72 hours after cardiac arrest. Data from randomized clinical trials of this intervention have been lacking.
METHODS: We randomly assigned comatose patients who had been resuscitated after an out-of-hospital cardiac arrest of presumed cardiac cause to device-based temperature control targeting 36°C for 24 hours followed by targeting of 37°C for either 12 or 48 hours (for total intervention times of 36 and 72 hours, respectively) or until the patient regained consciousness. The primary outcome was a composite of death from any cause or hospital discharge with a Cerebral Performance Category of 3 or 4 (range, 1 to 5, with higher scores indicating more severe disability; a category of 3 or 4 indicates severe cerebral disability or coma) within 90 days after randomization. Secondary outcomes included death from any cause and the Montreal Cognitive Assessment score (range, 0 to 30, with higher scores indicating better cognitive ability) at 3 months.
RESULTS: A total of 393 patients were randomly assigned to temperature control for 36 hours, and 396 patients were assigned to temperature control for 72 hours. At 90 days after randomization, a primary end-point event had occurred in 127 of 393 patients (32.3%) in the 36-hour group and in 133 of 396 patients (33.6%) in the 72-hour group (hazard ratio, 0.99; 95% confidence interval, 0.77 to 1.26; P = 0.70) and mortality was 29.5% in the 36-hour group and 30.3% in the 72-hour group. At 3 months, the median Montreal Cognitive Assessment score was 26 (interquartile range, 24 to 29) and 27 (interquartile range, 24 to 28), respectively. There was no significant between-group difference in the incidence of adverse events.
CONCLUSIONS: Active device-based fever prevention for 36 or 72 hours after cardiac arrest did not result in significantly different percentages of patients dying or having severe disability or coma. (Funded by the Novo Nordisk Foundation; BOX ClinicalTrials.gov number, NCT03141099.).
参考来源
- Hassager C, Schmidt H, Møller JE, et al. Duration of Device-Based Fever Prevention after Cardiac Arrest. N Engl J Med. 2022. PMID: 36342119. doi:10.1056/NEJMoa2212528
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。